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Abstract The clinical use of anthracyclines in cancer ther-
apy is limited by dose-dependent cardiotoxicity that
involves cardiomyocyte injury and death. We have tested
the hypothesis that anthracyclines affect protein degradation
pathways in adult cardiomyocytes. To this aim, we assessed
the effects of doxorubicin (Doxo) on apoptosis, autophagy
and the proteasome/ubiquitin system in long-term cultured
adult rat cardiomyocytes. Accumulation of poly-
ubiquitinated proteins, increase of cathepsin-D-positive
lysosomes and myofibrillar degradation were observed in
Doxo-treated cardiomyocytes. Chymotrypsin-like activity
of the proteasome was initially increased and then inhibited
by Doxo over a time-course of 48 h. Proteasome 20S pro-
teins were down-regulated by higher doses of Doxo. The
expression of MURF-1, an ubiquitin-ligase specifically tar-
geting myofibrillar proteins, was suppressed by Doxo at all
concentrations measured. Microtubule-associated protein 1
light chain 3B (LC3)-positive punctae and both LC3-I
and -II proteins were induced by Doxo in a dose-
dependent manner, as confirmed by using lentiviral ex-
pression of green fluorescence protein bound to LC3
and live imaging. The lysosomotropic drug chloroquine
led to autophagosome accumulation, which increased
with concomitant Doxo treatment indicating enhanced auto-
phagic flux. We conclude that Doxo causes a downregulation
of the protein degradation machinery of cardiomyocytes with
a resulting accumulation of poly-ubiquitinated proteins and
autophagosomes. Although autophagy is initially stimulated
as a compensatory response to cytotoxic stress, it is followed
by apoptosis and necrosis at higher doses and longer exposure
times. This mechanism might contribute to the late cardiotox-
icity of anthracyclines by accelerated aging of the postmitotic
adult cardiomyocytes and to the susceptibility of the aging
heart to anthracycline cancer therapy.
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Introduction
The anthracycline doxorubicin (Doxo) is a well-established
drug used clinically in cytotoxic antitumor therapy for sev-
eral types of cancers. Potentially life-threatening cardiotox-
icity remains a problem with the anthracyclines and limits
the cumulative dose that can be administered safely (Singal
and Iliskovic 1998). Several studies have evaluated the
incidence and risk of early clinical cardiotoxicity, as char-
acterized by arrhythmias, a reversible depression of contrac-
tile function and the more common late cardiotoxicity
(Bristow et al. 1984; Steinherz et al. 1991). Cardiac abnor-
malities have been observed years after treatment and seem
to occur independently of whether cardiac problems
appeared during initial therapy (Goorin et al. 1990). The
long-term effect of Doxo on the cardiovascular system is
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especially evident in young patients: 71% of children that
have been followed up for >15 years after doxorubicin
therapy develop cardiotoxicity (Steinherz et al. 1991). The
mechanisms of the cardiotoxicity of anthracyclines appear-
ing many years after treatment are not known. A loss of
cardiomyocytes by cell death shortly after the first anthracy-
cline treatment could be a likely cause but fails to explain
cases in which no cardiotoxicity was noticed initially; in-
deed, apoptosis was not demonstrated at lower cumulative
doses of doxorubicin in experimental models (Zhang et al.
1996). Further suggested mechanisms include the impair-
ment of cardiac progenitor cell function in juvenile hearts by
anthracyclines and persisting damage to mitochondrial
DNA, which would represent the basis of a self-perpetuating
mitochondrial dysfunction (Huang et al. 2010; Lebrecht and
Walker 2007). Elderly patients are generally more susceptible
to anthracycline cardiotoxicity because of comorbidities, such
as hypertension, diabetes and limited cardiac reserve (Aapro et
al. 2011). On the other hand, postmitotic and long-living cells
such as cardiomyocytes accumulate protein aggregates and
defective mitochondria with age, which could accelerate cell
death under stress conditions. A common observation illus-
trating normal age-related changes in the myocardium is the
augmentation of a non-degradable yellow-brown pigment
composed of lipid and oxidized protein residues, the so-
called lipofuscin, in cardiomyocytes of elderly people
(De Meyer et al. 2010; Powell et al. 2005). Lipofuscin gen-
eration is enhanced by reactive oxygen species (ROS). Oxi-
dative stress is also thought to be a general problem with
anthracyclines, since the quinone moiety of the molecule acts
as a catalyst for the formation of ROS (Doroshow and Davies
1986). In cardiomyocytes, increased levels of intracellular
calcium and ROS can trigger the activation of proteases that
cause damage to myofibrillar proteins, e.g., titin and lead to
contractile dysfunction (Lim et al. 2004; Timolati et al. 2009).
The ubiquitin/proteasome system represents the main degra-
dation pathway involved in the removal of oxidatively mod-
ified proteins (Grune et al. 2004), whereas (macro-) autophagy
is generally considered a proteasome-independent catabolic
mechanism for bulk degradation and routine turnover of larger
cell constituents (Glick et al. 2010; Xie et al. 2011). Previous
studies have shown an important role of the ubiquitin/
proteasome in the heart challenged by anthracyclines,
which have been proposed to induce a potentially harm-
ful over-activity of this protein degradation system in cardi-
omyocytes (Kumarapeli et al. 2005; Ranek and Wang 2009).
We have tested the hypothesis that anthracycline cancer
therapy modulates several protein degradation pathways in
adult cardiomyocytes. We have found that Doxo applied for
48 h causes dose-dependent effects, namely myofibrillar
disarray at lower doses and a downregulation of the
proteasome-ubiquitin system at higher doses with the result-
ing accumulation of poly-ubiquitinated proteins, cathepsin-
D-positive lysosomes and autophagosomes. Whereas pro-
teasome activity and autophagy are stimulated initially as a
compensatory response to cytotoxic stress and the accumu-
lation of oxidized proteins, this is followed by apoptosis and
necrosis at higher doses and longer exposure times.
Materials and methods
Isolation of adult rat ventricular cardiomyocytes
Adult (280–350 g) male Wistar rats from an in-house breed-
ing facility were killed by pentobarbital (Abbott Laborato-
ries) injection. The heart was excised and the aorta was
cannulated and retrograde perfused at 90 cm H2O pressure.
Isolation of calcium-tolerant adult rat ventricular myocytes
(ARVM) was achieved according to previously published
methods (Kondo et al. 1998). The cells were plated onto
laminin-coated (10 μg/ml mouse laminin, Invitrogen) cell
culture dishes (Nunc) and maintained in serum-containing
medium for the entire culture period. Culture medium was
based on M-199 (Amimed) and additionally contained 20
mM creatine (Sigma), 1% 100 U/ml penicillin/streptomycin
(Invitrogen), 20% preselected fetal calf serum (PAA Labo-
ratories) and 10 μM cytosine arabinoside (Sigma). All
experiments were carried out according to the Swiss animal
protection law and with the permission of the State Veteri-
nary Office. The investigation conformed to the “Guide for
the Care and Use of Laboratory Animals” published by the
US National Institutes of Health.
Immunocytochemistry and fluorescence microscopy
Cell cultures were washed with phosphate-buffered saline
(PBS), then fixed with 3% para-formaldehyde in PBS for
15 min, permeabilized with 0.2% Triton-X100 (Sigma) in
PBS for 10 min or with ice-cold methanol for 5 min, incu-
bated for 30 min with bovine serum albumin (Sigma) at
1 mg/ml in PBS at room temperature, incubated overnight
with primary antibodies at 4°C, washed three times with
PBS and incubated for 1 h with secondary antibodies cou-
pled to Alexa fluorescent dyes (Invitrogen). Preparations
were examined either by using an inverted microscope
(Leitz DM IL) and a 40× oil immersion lens (NA 1.3,
Olympus; see below) or on a Zeiss LSM 5 Exciter confocal
microscope using 40× or 63× Zeiss oil immersion lenses
(see below and Fig. S1). Monoclonal antibodies to myosin
heavy chain clone A4.1025 were obtained from Millipore
(catalog no. 05-716). Actin was detected by using polyclon-
al antibodies to all-actin (A2066, Sigma). Anti-myomesin
mouse monoclonal antibodies (clone B4) were a gift from
J.C. Perriard, ETH-Zurich, Switzerland. Monoclonal anti-
bodies, namely clone FK1 to poly-ubiquitinated protein
362 Cell Tissue Res (2012) 350:361–372
adducts, were obtained from Biomol. This antibody recog-
nizes K29-, K48- and K63-linked polyubiquitinated proteins
but not mono-ubiquitinated proteins or free ubiquitin (Fuji-
muro and Yokosawa 2005). Rabbit polyclonal antibodies to
subunits of the 20-S-proteasome core (catalog no. PW8155)
were from Biomol. Antibodies for Atg8/microtubule-as-
sociated protein 1 light chain 3B (LC3) were from
Abcam (polyclonal, catalog no. ab58610) or from nano-
tools (monoclonal, clone 2 G6). For immunocytochem-
istry, the anti-LC3 clone 2 G6 was used throughout.
Antibodies to rat cathepsin-D (clone R20) were from
Santa Cruz Biotechnology. Monoclonal antibodies to
titin I-band (clone 9D10) were obtained from the De-
velopment Studies Hybridoma Bank at the University of
Iowa and polyclonal antibodies to the titin M-line do-
main (M8) were a gift from Mathias Gautel, King’s
College, London. Secondary antibodies for immunocy-
tochemistry were conjugated with Alexa fluorescent
dyes (Invitrogen).
Pharmacologic treatments
Doxorubicin-hydrochloride (Doxo; Sigma) was dissolved
in water. Lactacystin and chloroquine were obtained
from Calbiochem (Merck group) and were dissolved in
dimethylsufoxide (DMSO).
Cell death and viability assays
TUNEL assay TUNEL (terminal deoxyribonucleotidyl-
transferase mediated D-uridine 5′-triphosphate nick-end
labeling) assay was performed according to the manu-
facturers instructions (“In situ cell death detection kit
AP”, Roche Applied Science), with the exception of
prolonged permeabilization. Incubation with DNAse-I
(Sigma) was used as a positive control for DNA nick
labeling. In order to avoid interference of red-fluorescent
nuclei in the counting of TUNEL-positive cells by fluores-
cence microscopy after Doxo treatment, conversion to an
alkaline-phosphatase-based detection system was performed
(5-bromo-4-chloro-3-indolyl-phosphate/nitroblue tetrazolium
substrate, Sigma).
Western blot analysis
Cells were quickly washed with ice-cold PBS and lysed by
using modified RIPA lysis buffer (1% NP-40, 0.2% SDS,
0.25% deoxycholic acid, 50 mM TRIS-HCl pH 7.4, 1 mM
EDTA, 150 mM NaCl, 1 mM NaF, 1 μg/ml leupeptin, 1 mM
phenylmethane sulfonylfluoride, 1 mM sodium orthovana-
date, 2 μg/ml pepstatin, 1 μg/ml aprotinin). For the analysis
of poly-ubiquitinated proteins by Western blot (see below),
cells were lysed in cold lysis buffer containing 3.7 M urea,
134.6 mM TRIS, 5.4% SDS, 2.3% NP-40, 4.45% beta-
mercaptoethanol, 4% glycerol, 6 mg/100 ml bromophenol
blue. Cell lysates were boiled with a loading buffer contain-
ing 3.3% glycerin, 1% SDS 20 mM TRIS pH 6.8, 23 mM β-
mercaptoethanol (freshly added) and 0.4 mg/ml bromophe-
nolblue). Proteins were separated by SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) by using precast 4%–20%
gradient gels (Lonza, Invitrogen) and blotted to nitrocellu-
lose (Whatman) or polyvinylidene difluoride membranes
with low autofluorescence (Millipore). Immunodetection
was carried out after the blocking of the membrane in 5%
milk or gelatin in TTBS (20 mM TRIS base pH 7.5,
150 mM NaCl, 0.05% Tween-20). Signals from polyclonal
antibodies to all-actin (A2066, Sigma) or monoclonal anti-
bodies to sarcomeric actin (A2172, Sigma) were used as a
reference for normalizing the protein amount in each lane.
For the visualization of signals, a LiCor Odyssey infra-red
imaging system was used with secondary antibodies cou-
pled to IRDye fluorescent dyes (LiCor).
Proteasome activity
The chymotrypsin-like activity of the proteasome was mea-
sured by monitoring the cleavage of the fluorogenic sub-
strate Suc-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin
(Chemicon/Millipore; catalog no. APT280). The irreversible
proteasome inhibitor lactacystin was used as a negative
control. DMSO, the solvent used for lactacystin treatment,
was included in control cultures. Freshly made protein
extracts from ARVM containing equal amounts of protein
measured by the Bradford assay (BioRad) in a photometer
were incubated for 60 min with assay buffer and substrate at
37 °C in the dark. The lysis buffer contained 50 mM HEPES
(pH 7.5), 5 mM EDTA, 150 mM NaCl, 2 mM ATP (freshly
added) and 1% Triton X-100. The amount of free 7-amino-
4-methylcoumarin (AMC) as a measure of the chymotrypsin-
like activity of the 20S proteasome was assessed in a Safire
microplate fluorescence reader (Tecan).
RNA isolation and real-time polymerase chain reaction
RNA isolation from cell cultures was performed with a kit
from Qiagene (RNeasy fibrous tissue kit). RNA quality was
tested by measuring the ratio 260/280 nm in a UV-
photometer. Reverse transcription was performed by using
the iScript cDNA synthesis kit (BioRad). Primers purified
by high-pressure liquid chromatography were ordered from
TIB Molbiol. Gene sequences were retrieved from the
National Center for Biotechnology Information (NCBI)
database. Primers were designed by using the software
“Primer 3” (Whitehead Institute for Biomedical Research) and
tested for specificity with BLAST (NCBI) searches against rat
genome. Real time polymerase chain reactions (PCRs) were
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performed with the iCycler (Biorad) and iQ SYBR Green mix
including iTaq-polymerase. For standard PCR amplification,
the Ex TAq and additional chemicals from TaKaRa Bio were
employed. The geometric mean of the housekeeping genes
18S and hypoxanthine phosphoribosyl-transferase (HPRT)
was used for normalization. The primer for MURF-1
(muscle-specific RING finger protein 1) was chosen
according to previously published sequences (Adams et
al. 2007). Primers are listed as follows: 18s, X01117,
forward, gtaacccgttgaaccccatt, reverse, ccatccaatcggtagtagcg,
HPRT, NM012583, forward tgtggccagtaaagaactagca, reverse
gacaatctacctgacggtaggc, MURF-1, NM080903.1 forward
tccaaggacagaagactgaact, reverse tggaagcttctacaatgctctt.
Lentiviral expression of green fluorescence protein bound
to LC3 and live imaging
Cardiomyocytes were cultured on laminin-coated glass bot-
tom dishes (Greiner bio-one) in standard medium and trans-
duced with lentiviral particles at a multiplicity of infection
of 50. Lentiviral particles carrying a construct of TagGFP2-
LC3 driven by the elongation factor-1 promoter (Millipore
LentiBrite) were applied for 24 h, the medium was changed
and the pharmacological treatment was started after another
24 h. Live images were obtained by using an inverted
microscope (Leitz DM IL), Olympus 40× objective and a
Nikon Coolpix990 camera.
Statistics
All values are expressed as mean±SEM. Statistical analysis
of differences observed between the groups was performed
by Student’s unpaired t-tests or by analysis of variance,
followed by Bonferroni’s repeated measurement compari-
sons, when appropriate. Statistical significance was accepted
at the level of P<0.05.
Results
Doxo-induced changes of myofibrillar structure
ARVM in long-term culture in the presence of fetal calf
serum assume a polygonal shape, form intercalated disc-
like structures and myofibrils and resume contractile activity
(Eppenberger and Zuppinger 1999). Untreated cardiomyo-
cytes showed a well-developed non-sarcomeric cytoskele-
ton and myofibrils after 14 days in culture, as demonstrated
by immunocytochemistry with antibodies for all-actin and
myosin heavy chains (Fig. 1a). Treatment with 10 μMDoxo
for 48 h resulted in a clumping of cytoskeletal elements. The
sarcomeric striation of myofibrils disappeared to a large
extent and the overall staining for myosin was reduced
(Fig. 1b). At this dose of Doxo, changes in the morphology
of nuclei became apparent and 4,6-diamidino-2-phenylin-
dole (DAPI) labeling of nucleic acids was less homoge-
neous than that in controls. Potential mechanisms of the
observed cytoskeletal damage after Doxo treatment involv-
ing increased cytoplasmic calcium, activation of calpain-I
and the cleavage of titin have been investigated previously
in this model (Lim et al. 2004; Timolati et al. 2009). A
group of Doxo-treated ARVM presumably showing differ-
ent stages of cytoskeletal degradation is shown in the elec-
tronic supplementary material (Fig. S1a-a’’’).
DNA degradation
For measuring DNA degradation as a marker of apoptosis,
we used the TUNEL assay, with DNase serving as a positive
control (Fig. 2). A significant increase in the frequency of
TUNEL-positive cardiomyocytes was observed at 10 μM
and higher doses of Doxo for 48 h. Other viability param-
eters such as mitochondrial respiration and plasma mem-
brane integrity have demonstrated a dose-dependent
increase of cell death with doses of >10 μM/48 h in previous
studies in our laboratory (Timolati et al. 2009).
Doxo induces polyubiquitin aggregates
and cathepsin-D-positive lysosomes
Granular cytoplasmic inclusions of ubiquitinated proteins,
also called aggresomes, have been observed in cardiac tissue
taken from patients suffering from ischemic cardiomyopa-
thy or dilated cardiomyopathy (Knaapen et al. 2001) and in
pressure-overload hypertrophy and after glucose deprivation
in experimental models (Marambio et al. 2010; Tannous et
al. 2008). We tested the integrity of myofibrils by using the
M-line protein myomesin as a marker and examined the
localization and amount of polyubiquitinated proteins in
the same cells treated with increasing doses of Doxo
(Fig. 3). The antibody FK1 recognizes K29-, K48- and
K63-linked polyubiquitinated proteins but not mono-
ubiquitinated proteins or free ubiquitin (Fujimuro and
Yokosawa 2005). ARVM were cultured until day 12
and then treated with 1 μM (Fig. 3b, b’) or 10 μM Doxo
(Fig. 3c, c’). Polyubiquitin labeling was found as diffuse
staining in the cytoplasm of untreated ARVM with intact
myofibrils (Fig. 3a, a’). Occasionally, the signals from the
anti-polyubiquitin antibodies showed a sarcomere-like striated
pattern in untreated ARVM (not shown). Degradation of
myofibrils with concomitant accumulation of polyubiquiti-
nated proteins occurred even at the sub-apoptotic dose of
1 μM Doxo (Fig. 3b, b’). Signals from aggregates of poly-
ubiquitinated proteins and granular aggregates of myomesin
were colocalized in Doxo-treated ARVM (Electronic Supple-
mentary Material, Fig. S1b). The distribution of large
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inclusions of polyubiquitinated proteins was heterogeneous in
cell populations. Cells with large aggresomes always showed
myofibrillar changes but not vice-versa. In Doxo-treated
ARVM, red fluorescence in the nuclei was observed indicat-
ing the accumulation of anthracycline. Nuclear Doxo fluores-
cence was usually seen in paraformaldehyde-fixed cells
(Fig. 3b/b’, c/c’) but not in methanol-fixed ARVM (Fig. 3e).
The aspartic proteases of the cathepsin family participate in
maintaining the homeostasis of the metabolism of the cell by
the bulk-degradation of aggregated proteins and entire organ-
elles (Gevers 1984). Cathepsin-D-positive vesicles were
found in untreated ARVM but increased in number and size
with Doxo treatment, especially in the perinuclear area
(10 μM/48 h; Fig. 3d, e).
Modulation of the ubiquitin/proteasome system by Doxo
We assessed the state of the ubiquitin-proteasome system in
ARVM treated with Doxo (Fig. 4). The 20S proteasome
core components were found in a cross-striated pattern and
at intercalated disc-like structures in untreated ARVM
(Fig. 4a). A similar pattern was detected for ubiquitin in
cardiomyocytes (not shown). The observed localization of
the ubiquitin/proteasome system in ARVM in long-term
culture was in agreement with previous reports of its local-
ization in ventricular tissue in vivo (Hilenski et al. 1992).
The same 20S proteasome core proteins were analyzed by
using Western blot after Doxo treatment for 48 h, normal-
ized to sarcomeric actin (Fig. 4b). No significant change
occurred at lower concentrations of Doxo but a significant
decrease took place at concentrations associated with irre-
versible cell death. We then assessed the chymotrypsin-like
activity of the proteasome with an assay measuring the
degradation of the sequence Suc-Leu-Leu-Val-Tyr in cellu-
lar lysates (Fig. 4c, d). The same amount of total protein, as
measured by the Bradford assay, was used for each
Fig. 1 Doxorubicin (Doxo) induces cytoskeleton changes with loss of
myofibrils and clumping of the non-sarcomeric cytoskeleton. a Un-
treated cells. b Adult rat ventricular myocytes (ARVM) were cultured
for 12 days and then treated for 48 h with 10 μM Doxo. Myofibrils
were labeled with antibodies to anti-myosin heavy chain (green) and
actin filaments were labeled with anti-all-actin antibodies (red); nuclei
were stained with DAPI (blue)
Fig. 2 Doxo induces DNA fragmentation in ARVM in a dose-
dependent manner (Ctrl control). ARVM were treated for 48 h
before fixation and terminal deoxyribonucleotidyl-transferase me-
diated D-uridine 5′-triphosphate nick-end labeling (TUNEL) assay.
**P<0.01, ***P<0.001, n04
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condition. In the first assay, we measured the activity in a
short-term treatment with either 1 or 50 μM Doxo and
expressed the result as percent of the activity in an untreated
sample at the same time point (Fig. 4c). The lower Doxo
concentration resulted in a generally elevated activity from
the beginning, which slowly declined after 18 h. The high
dose increased the activity until 3 h and then the activity
declined rapidly. These results were confirmed in a second
assay in which the activity was measured (shown as abso-
lute values) after 48 h (Fig. 4d). The measured activity was
unchanged below 10 μM Doxo and then declined rapidly at
higher concentrations. The irreversible proteasome inhibitor
lactacystin served as a negative control. The results from the
proteasome Western blots (Fig. 4b) indicated that not only
the activity but also the proteasome itself was affected in the
cells treated with extremely high concentrations of Doxo.
We then assessed polyubiquitinated proteins by Western blot
after Doxo treatment in the range of 1–20 μM for 48 h
(Fig. 4e). The most intense labeling by the FK1 antibody
was observed with 10 μM Doxo treatment in the molecular
weight range above 100 kDa. Longer exposure times
resulted in a smear over the entire weight range (not shown).
Apart from the proteasome machinery itself, a series of
enzymes play a crucial role in the ubiquitination of target
proteins and therefore in protein turnover. The specificity of
the ubiquitination lies primarily with the ubiquitin E3
ligases and MuRFs, especially MURF-1, have been identi-
fied as E3 ligases targeting myofibrillar proteins such as
actin, titin and others in skeletal muscle and in the myocar-
dium (Gregorio et al. 2005; Mrosek et al. 2007; Polge et al.
2011). We have measured the expression of MURF-1 by
real time PCR in ARVM after Doxo treatment for 48 h
(Fig. 4f). MURF-1 mRNA was significantly reduced by
Doxo at all concentrations measured.
Doxo increases autophagy in ARVM
LC3, the mammalian homolog of yeast Atg8, was originally
identified as a binding partner of microtubule-associated
proteins, until its role during the formation of autophagoso-
mal membranes was discovered. Cytosolic LC3-I undergoes
conjugation to highly lipophilic phosphatidylethanolamine
by Atg7, Atg3 and the Atg12-Atg5/Atg16 complex to form
the autophagosome-associated LC3-II, which runs different-
ly from LC3-I in SDS-PAGE and serves as a marker of
autophagosomes in immunofluorescence microscopy
(Kabeya et al. 2000; Mizushima et al. 2001). The distribu-
tion and appearance of LC3 in untreated ARVM and in cells
exposed to 10 μM Doxo for 48 h is demonstrated in Fig. 5a,
b, respectively. LC3-positive puncta, often single spots on a
low cytoplasmic background, were occasionally also ob-
served in untreated cells; however, the number of LC-
positive vesicles after Doxo treatment increased, as did the
cytoplasmic staining for LC3. Interestingly, filamentous
structures reminiscent of microtubules were observed in
some of the Doxo-treated ARVM showing an increase of
puncta and cytoplasmic staining (Fig. 5b). We then assessed
LC3-I/II by Western blotting (Fig. 5c). Doxo treatment for
48 h generally increased LC3. However, different antibodies
showed distinctive affinities to LC3-I/II: polyclonal anti-
body ab58610 mainly recognized LC3-I in ARVM, whereas
monoclonal antibody clone 2G6 demonstrated the increase
of LC3-II in the cells. Densitometry of signals from the
Fig. 3 Accumulation of aggresomes marked by polyubiquitinated
proteins, loss of myofibrils and increase of cathepsin-D-positive lyso-
somes after Doxo treatment. a/a’-c/c’ ARVM were treated with Doxo
(a/a’ untreated, b/b’ 1 μM, c/c’ 10 μM) for 48 h and then immunos-
tained for myomesin (red) or polyubiquitinated proteins (green). d, e
ARVM were immunostained for cathepsin-D (green). d Untreated. e
10 μM Doxo
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antibody 2G6 normalized to all-actin showed a significant
increase of LC3-II at 20 μM Doxo (Fig. 5d). Additional
experiments examining green fluorescence protein (GFP)-
LC3 expression after lentiviral transduction of cardiomyo-
cytes demonstrated LC3 localisation in live cells without
possible artifacts being introduced by fixation or the use of
antibodies (Fig. 5f–h). GFP-LC3 was observed in puncta but
mainly displayed a diffuse cytosolic distribution (Fig. 5f).
After treatment with Doxo (Fig. 5g), no diffuse fluorescence
was observed but rather GFP-LC3 puncta similar to the
immunofluorescence results. Treatment with chloroquine,
an inhibitor of autophagosome/lysosome fusion, led to large
cytosolic vacuoles, which appeared outlined by the GFP-
LC3 signal in the live cells (Fig. 5h). Increased LC3-II
levels might have been associated with either enhanced
autophagosome synthesis or reduced autophagosome
turnover, perhaps attributable to delayed trafficking to the
lysosomes, reduced fusion between compartments, or im-
paired lysosomal proteolytic activity (Barth et al. 2010). We
therefore sought a method to discern these two situations.
The inhibition of autolysosome function by using an inhib-
itor such as chloroquine or bafilomycin leads to an accumu-
lation of LC3-positive autophagosomes as a sign of efficient
autophagic flux, whereas the absence of such an accumula-
tion, either over time or in combination with a hypothetical
modulator of autophagy, indicates a failure of the autopha-
gic machinery earlier in the process. We used chloroquine
for the purpose of elucidating changes of autophagic flux
caused by Doxo treatment in ARVM (Fig. 6). Cells were
immunostained for LC3 by using antibody clone 2G6 and
for polyubiquitinated proteins. Chloroquine alone at 10 μM
for 48 h led to an increase and homogeneous distribution of
Fig. 4 Effects of Doxo on the
proteasome/ubiquitin system in
ARVM. a Subcellular
localization of the 20S
proteasome core components in
untreated ARVM. Labeling was
mainly found in a cross-striated
pattern and at the intercalated
disc-like structures (black ar-
row). b Densitometry and rep-
resentative Western blot for the
20S proteasome normalized to
sarcomeric actin. ARVM were
treated for 48 h with the indi-
cated Doxo doses. c Proteasome
activity in lysates was measured
after the indicated times for 1
and 50 μM Doxo. Results are
shown normalized to untreated
cells of the same age. d Protea-
some activity after treatment
with the indicated Doxo doses
for 48 h. The irreversible pro-
teasome inhibitor lactacystin
was used as a negative control
(ns not significant). e Western
blot for polyubiquitinated pro-
teins in ARVM treated with the
indicated Doxo doses for 48 h
(CTL control). f Gene expres-
sion of MURF-1 was normal-
ized to the expression of two
house-keeping genes and to
untreated ARVM. *P<0.05,
**P<0.01, n04
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LC3 puncta. Polyubiquitinated proteins were found in most
cells in the form of smaller aggregates that co-localized with
the autophagosome marker LC3 but were overall not signif-
icantly increased (Fig. 6a/a’). The combination of chloro-
quine at 20 μM and Doxo at 10 and 20 μM showed a dose-
dependent increase of LC3 and aggregates of polyubiquiti-
nated proteins that increasingly colocalized with increased
Doxo concentration (Fig. 6b, c)
Discussion
We report the effects of anthracyclines on protein degrada-
tion systems and cell death in cultured adult cardiomyo-
cytes. We decided to use cells from adult animals for this
study, although technically more challenging, because dif-
ferences in cell cycle activity and gene expression between
immature and differentiated cells are common. Cell models
showing active proliferation might respond differently to
cancer therapies by stalled mitosis and subsequent cell
death, which is not necessarily the case in terminally differ-
entiated cells. This basic principle is illustrated by the action
of antimetabolites and proliferation inhibitors such as Ara-C
that are sometimes added to primary cardiomyocyte cultures
for limiting the growth of non-myocytes after isolation.
Occasionally, differences between neonatal and adult cardi-
omyocytes have been investigated in detail and significant
dissimilarities have been noted, for instance, for calcium han-
dling and the regulation of Doxo-induced apoptosis (Konorev
et al. 2008; Poindexter et al. 2001). An overall higher sensi-
tivity of neonatal cardiomyocytes for anthracycline-induced
apoptosis has been noted in a previous study: neonatal cardi-
omyocytes exposed to 0.5 μM doxorubicin for 24 h
exhibit a nearly three-fold increase of apoptotic cells
as quantified by flow cytometry, whereas adult cardio-
myocytes do not show cell death under this condition
(Lim et al. 2004). Anthracyclines have been reported to
reach peak concentrations in plasma of up to 5 μM and
the values are generally in the range of 1-2 μM in
patients after bolus injection (Gewirtz 1999). For in situ
models with a short life time and thus short time of
drug persistence, such as the isolated perfused heart,
muscle strips, or isolated mitochondria, often supraclin-
ical Doxo concentrations up to several hundreds of micro-
moles have been applied (Tokarska-Schlattner et al. 2006).
Although cell death in cardiomyocytes has been reported in
Fig. 5 Doxo induces LC3-I/II-
and LC3-positive punctae in
ARVM. a–c ARVM were cul-
tured for 12 days and then trea-
ted with 0, 10, or 20 μM Doxo
for 48 h and immunostained for
LC3. Note the increased LC3-
positive punctae, diffuse stain-
ing and occasional filamentous
structures (white arrows in b). d
Representative Western blots
for Doxo-treated ARVM tested
with two different antibodies
showing differential labeling of
LC3-I/II. e Densitometry for
LC3 with antibody clone 2 G6.
f–h Live cardiomyocytes
expressing GFP-LC3 after len-
tiviral transduction and phar-
macologic treatment for 48 h. f
Untreated cells. g Doxo at
1 μM. h Chloroquine at 20 μM
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many different laboratory models (Singal and Iliskovic 1998),
the use of extremely high concentrations in cell culture experi-
ments might lead to an overestimation of cell death as a
mechanism of anthracycline-induced cardiotoxicity. There-
fore, we have chosen a range of concentrations, for most
experiments in this study, starting from below the above-
mentioned numbers found in plasma up to supraclinical con-
centrations applied for a relatively long period of time (usually
48 h) in culture.
A larger body of literature is available describing the
cardiotoxic mechanisms of anthracyclines at the level of
the muscle cell (for a review, see Sawyer et al. 2010).
Recently, other stress-related pathways than irreversible cell
death have been investigated, in the hope that ways can be
found to repair and rescue myocardial tissue. Our results
demonstrate that LC3-positive puncta and total LC3 in-
crease as a result of anthracycline treatment in cultured
ARVM. This result has been confirmed by Western blotting
for LC3 by using different antibodies. To test whether the
choice of antibodies or the fixation of the cells causes
artifacts in the localization of LC3-positive puncta, we have
used a GFP-LC3 construct, lentiviral transduction and live
imaging of cardiomyocytes. Although this method is also
not devoid of possible distorting effects, such as the forma-
tion of GFP-aggregates at high expression levels or effects
of the viral vectors (Klionsky et al. 2008), the observed
alterations between the control situation and anthracycline-
treated cells, such as the observed switch from a diffuse
cytosolic GFP-LC3 distribution to a punctate one, demon-
strates the induction of autophagy by Doxo in these cells.
Additionally, cathepsin-D-positive lysosomes are increas-
ingly found with a perinuclear distribution and the lysoso-
motropic drug chloroquine leads to autophagosome
accumulation, which increases with concomitant Doxo
treatment indicating enhanced autophagic flux.
Generally, the functional role of enhanced autophagy in
the heart is still unclear and studies have reported conflicting
results. Should autophagy be regarded as a protective mech-
anism or as a process contributing to disease progression?
Earlier studies have described autophagy-related changes in
human failing hearts as a form of cell death (Hein et al.
2003; Knaapen et al. 2001; Kostin et al. 2003). Current
evidence indicates that autophagic activity under physiolog-
ical conditions is important for cellular homeostasis, where-
as excessive autophagy is detrimental (Nishida et al. 2009;
Kobayashi et al. 2010). Autophagy predominantly functions
as a pro-survival pathway during nutrient deprivation and
other forms of cellular stress, as has been demonstrated in a
number of model systems and in rare human diseases.
However, when autophagy is rigorously activated, the
Fig. 6 Chloroquine and Doxo
increase autophagosome
accumulation indicating higher
autophagic flux in treated
ARVM. ARVM were treated
with chloroquine 20 μM and
Doxo 1 μM in a/a’, with
chloroquine 20 μM and Doxo
10 μM in b/b’ and with Doxo
20 μM and chloroquine 20 μM
for 48 h in c/c’. Cells were then
fixed and immunostained for
LC3 (green) and for
polyubiquitinated proteins (red)
and single optical sections were
taken by confocal microscopy.
Co-localizing signals appear in
yellow in the merged images
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autophagic machinery might also be used for self-
destruction (Nemchenko et al. 2011). Hence, when autopha-
gic cell death occurs in cardiac cells, it might contribute to
the progress of heart failure. On the other hand, if the rate of
autophagy declines with age, this progressively leads to the
inability to process and remove accumulated “waste”, such
as lipofuscin or the polyubiquitinated protein aggregates
that have been found after Doxo treatment in our experi-
ments. The progress of these changes results in en-
hanced oxidative stress, decreased ATP production,
collapse of the cellular catabolic machinery and hence, necro-
sis or apoptosis. By contrast, in load-induced heart failure, the
extent of autophagic flux can rise to maladaptive levels (Zhu
et al. 2007). Accordingly, the development of therapies that
up-regulate the repair qualities of the autophagic process and
down-regulate the cell death aspects would be of great value
in the treatment of heart failure (De Meyer et al. 2010). In this
context, we consider it of interest to compare features of
normal aging of the myocardial tissue with effects of Doxo-
induced cardiotoxicity. Protein aggregation seems to be a
common feature of physiological aging. Even greater cell
damage indicated by the loss of myofibrils, the swelling of
mitochondria and the accumulation of lipofuscin granules is
seen in an older adriamycin-treated group of animals
(Weinberg and Singal 1987). Thus, the loss of protea-
some function might impair the ability of myocytes to mount
an appropriate response to stress, thereby enhancing the sus-
ceptibility of the aging heart to cardiovascular disease
(Bulteau et al. 2002). The combination of these factors
means that the natural decline in cardiac reserve is
accelerated by anthracycline-induced cardiotoxicity.
The ubiquitin-proteasome system plays an important role
in the heart for the continuous degradation and removal of
oxidized or misfolded proteins (for reviews, see Powell
2006; Wang et al. 2008). In heart failure, a disturbed balance
between a high rate of ubiquitination and inadequate degra-
dation of ubiquitin/protein conjugates might finally contrib-
ute to autophagic cell death and the loss of cardiomyocytes
in the tissue (Kostin et al. 2003). In this study, we first
measured chymotrypsin-like activity of the proteasome over
a wide range of Doxo concentrations in ARVM after 48 h
incubation. The results showed no change at lower concen-
trations and a downregulation in the higher range when the
majority of cells were TUNEL-positive (Figs. 2, 4). These
initial results seemed to be at odds with publications by the
group of Wang (Kumarapeli et al. 2005) who propose an
activation of proteasome activity in the heart by anthracy-
clines. However, a time-course experiment with either a
smaller concentration of 1 μM (considered clinically rele-
vant by all investigators) or an extremely high dose has
revealed that proteasome activity increases only initially
and then decreases and that an extremely high Doxo con-
centration leads only to the inhibition of the activity or to the
degradation of the proteasome itself, as indicated by the
Western blotting experiment for 20S proteasome proteins.
Inadequate proteolytic function of the ubiquitin-proteasome
system might then lead to the activation of autophagy.
Polyubiquitinated proteins were increased by Doxo treat-
ment in our experiments and were clearly recognized as
aggregates in cardiomyocytes showing concomitant myofi-
brillar changes. The mRNA of the sarcomere-associated
ubiquitin ligase MURF-1 was found to be decreased at all
concentrations of Doxo in ARVM. Interestingly, muscle
actin is polyubiquitinated in vitro and in vivo and is targeted
for breakdown by MURF-1 (Polge et al. 2011). Another E3
ubiquitin ligase important in muscle atrophy, atrogin-1, has
been found to be increased by Doxo in neonatal rat cardio-
myocytes and in mice but not MURF-1 (Yamamoto et al.
2008). Considering the previously observed myofibrillar
degradation by the activation of calpain-1 and the presence
of damaged mitochondria even at lower concentrations of
Doxo in ARVM, the need for the removal of protein “waste”
after anthracycline exposure is evident. Autophagy is able to
remove protein aggregates to some extent, as has been
reported in a study of glucose deprivation of cultured neo-
natal cardiomyocytes and autophagy inhibitors such as 3-
methyladenine worsen the state of the cells (Marambio et al.
2010). However, this pro-survival system might become
excessively active and lead to apoptosis as a consequence
of maladaptive autophagy.
Our study has confirmed the need for an efficient and
intact system of protein “waste” removal in adult mamma-
lian cardiomyocytes under cytotoxic stress conditions such
as anthracycline cancer therapy. Both the ubiquitin-
proteasome system and autophagy are challenged in this
situation and even if the amount of drugs might not reach
the same higher concentration in the hearts of patients as
under some of our experimental conditions, a repeated
exposure carries the risk of cellular injury and cell
death. However, encouragingly, new tools and therapies
are currently in development for assessing autophagic
activity in order either to limit excessive activation or to
use the activation of this cellular pathway as a potential
cardioprotective strategy in patients.
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